ABSTRACT… Objectives: To evaluate the immediate outcomes of PTMC in patients with severe mitral valve stenosis. Study Design: Cross-sectional study. Setting: Ninety (90) subjects who underwent PTMC in Cardiac Catheterization Department of CPE Institute of Cardiology. Period: June 2008 to June 2011. Methods: Patients with severe MS having mitral valve (MV) area <1.0 cm 2 and having morphology suitable for PTMC in the absence of regurgitation and left atrial clot were included in this study. An increase in mitral valve area more than 50% of the baseline area without the development of moderate to severe MR was considered as the procedural success. Data were analyzed using SPSS V19. Pre and post procedural outcomes were measured using paired sample t-test. Results: There were a total number of ninety (90) patients in this study. Mean age of subjects was 28.08+9.61 years. There were more females 59 (65.5%) as compared to only 31 (34.5%) males. There was significant increase in mitral valve area, 1.83+0.36 cm 2 post-PTMC versus 0.63+0.17 cm 2 pre-PTMC (p-value <0.001). There was significant decrease in Peak pressure gradient (PPG) from 28.31+6.01 mmHg to 12.85+3.20 mmHg after PTMC (p-value <0.001). There were also significant reductions in mean pressure gradient and pulmonary artery systolic pressures after PTMC with p-value <0.001 and <0.001 respectively. PTMC was successful in 87 (97.7%) patients and it failed in only 3 (3.3%) patients. Conclusion: PTMC is an excellent treatment option regarding optimal outcomes and success rate in patients of severe mitral stenosis especially when performed by experienced interventionists. Key words:Mitral Stenosis, Percutaneous Transvenous Mitral Commissurotomy (PTMC), rheumatic fever, rheumatic heart disease.

Objectives: To evaluate the immediate outcomes of PTMC in patients with severemitral valve stenosis. Study Design: Cross-sectional study. Setting: Ninety (90) subjects whounderwent PTMC in Cardiac Catheterization Department of CPE Institute of Cardiology. Period:June 2008 to June 2011. Methods: Patients with severe MS having mitral valve (MV) area <1.0cm2 and having morphology suitable for PTMC in the absence of regurgitation and left atrial clotwere included in this study. An increase in mitral valve area more than 50% of the baseline areawithout the development of moderate to severe MR was considered as the procedural success.Data were analyzed using SPSS V19. Pre and post procedural outcomes were measured usingpaired sample t-test. Results: There were a total number of ninety (90) patients in this study.Mean age of subjects was 28.08+9.61 years. There were more females 59 (65.5%) as comparedto only 31 (34.5%) males. There was significant increase in mitral valve area, 1.83+0.36 cm2post-PTMC versus 0.63+0.17 cm2 pre-PTMC (p-value <0.001). There was significant decreasein Peak pressure gradient (PPG) from 28.31+6.01 mmHg to 12.85+3.20 mmHg after PTMC(p-value <0.001). There were also significant reductions in mean pressure gradient andpulmonary artery systolic pressures after PTMC with p-value <0.001 and <0.001 respectively.PTMC was successful in 87 (97.7%) patients and it failed in only 3 (3.3%) patients. Conclusion:PTMC is an excellent treatment option regarding optimal outcomes and success rate in patientsof severe mitral stenosis especially when performed by experienced interventionists.

placed under-expanded stent and 11% had severely calcified ISR. Procedural success was high (94%), however, reasons for failure/abandonment included: (i) intra-procedural ischaemia with significant residual stenosis, (ii) prolonged procedural time, ischaemia and resistant stent under-expansion and (iii) prolonged procedural time, dissection with no-reflow, in the setting of a chronic total occlusion (CTO). Complications Included Coronary dissection (13%) of which the majority were successfully treated with conservative measures and coronary perforation (2%) which was treated with prolonged balloon inflation. At a mean follow up of 10 months, 23% underwent planned/staged-PCI, 4% underwent CABG and there were 2 (4%) deaths. There was a 51% reduction in CCS angina class from 2.9 (prior to IVL) to 1.4 (post IVL), p<0.00001. Conclusions The use of coronary IVL is a very effective percutaneous therapy for severe CAC. This cohort shows high procedural success with IVL and a significant reduction in CCS angina class at follow-up.